SS47 (TFA)

SS47 TFA, a PROTAC-based HPK1 degrader, exerts proteasome-mediated HPK1 degradation. The degradation of HPK1 via SS47 also significantly enhances the in vivo antitumor efficacy of BCMA CAR-T cell research. HPK1, an immunosuppressive regulatory kinase, is a promising target for cancer immunotherapies[1]. SS47 (TFA) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Product Specifications

UNSPSC

12352005

Target

MAP4K; PROTACs

Type

Reference compound

Related Pathways

MAPK/ERK Pathway; PROTAC

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/ss47-tfa.html

Purity

99.88

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

O=C1N(C(CC2)C(NC2=O)=O)C(C3=C1C=CC=C3OCCOCCOCCOCCOCCC(N4CCC(C5=NC=C(C6=CC(OCC7=CC=CC(C#CC(C)(O)C)=C7)=C(N)N=C6)S5)CC4)=O)=O.OC(C(F)(F)F)=O

Molecular Formula

C51H57F3N6O14S

Molecular Weight

1067.09

References & Citations

[1]Jingwen Si, et al. Hematopoietic Progenitor Kinase1 (HPK1) Mediates T Cell Dysfunction and Is a Druggable Target for T Cell-Based Immunotherapies. Cancer Cell. 2020 Oct 12;38 (4) :551-566.e11.